Aeglea Bio Therapeutics Financials

Aeglea Bio Stock Summary

Aeglea Bio competes with Edgewise Therapeutics, Ikena Oncology, Design Therapeutics, Xilio Development, and Senti Biosciences. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea Biothera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.

Aeglea Bio Key Financial Ratios

Aeglea Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Aeglea Bio's current stock value. Our valuation model uses many indicators to compare Aeglea Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aeglea Bio competition to find correlations between indicators driving Aeglea Bio's intrinsic value. More Info.Aeglea Bio Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Aeglea Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.